Current Report Filing (8-k)
June 15 2020 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2020
SATSUMA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39041
|
|
81-3039831
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 410-3200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock
|
|
STSA
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On June 12, 2020, Satsuma Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting). At the
Annual Meeting, the Companys stockholders voted on two proposals, each of which is described in more detail in the Companys definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 24,
2020. Only stockholders of record as of the close of business on April 13, 2020, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 17,387,847 shares of the Companys common
stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal 1. The election of three Class I directors to hold office until the 2023 annual meeting of stockholders or until their respective
successor is elected:
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker
Non-Votes
|
|
John Kollins
|
|
|
14,650,063
|
|
|
|
130,522
|
|
|
|
476,723
|
|
Thomas King
|
|
|
14,649,591
|
|
|
|
130,994
|
|
|
|
476,723
|
|
Elisabeth Sandoval
|
|
|
13,554,452
|
|
|
|
1,226,133
|
|
|
|
476,723
|
|
Proposal 2. The ratification of the selection, by the audit committee of the board of directors of the Company, of KPMG
LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020:
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
15,256,980
|
|
0
|
|
328
|
As a routine proposal under applicable rules, no broker non-votes were recorded in
connection with this proposal.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SATSUMA PHARMACEUTICALS, INC.
|
|
|
|
|
Date: June 15, 2020
|
|
|
|
By:
|
|
/s/ Tom ONeil
|
|
|
|
|
|
|
Tom ONeil
Chief Financial
Officer
|
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Sep 2023 to Sep 2024